Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors

This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.

Study Overview

• Status: Terminated
• Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Stage IV Breast Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIIC Breast Cancer; Recurrent Breast Cancer; Recurrent Ovarian Epithelial Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer; Stage IV Gastric Cancer; Recurrent Colon Cancer; Recurrent Rectal Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Germ Cell Tumor; Adenocarcinoma of the Stomach; Ovarian Mucinous Cystadenocarcinoma; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier
• Intervention / Treatment: Other: laboratory biomarker analysis; Drug: oxaliplatin; Other: pharmacological study; Drug: capecitabine; Drug: veliparib

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of ABT-888 (veliparib) in combination with oxaliplatin and capecitabine in advanced solid tumors.

SECONDARY OBJECTIVES:

I. To evaluate the pharmacokinetics of ABT-888, oxaliplatin, and capecitabine when administered concomitantly.

II. To evaluate the safety and tolerability of the ABT-888 in combination with capecitabine and oxaliplatin.

III. To assess for evidence of anti-tumor activity with this combination, per tumor measurements using RECIST criteria, in these patients.

TERTIARY OBJECTIVES:

I. To assess the inhibition of poly(ADP-ribose) polymerase (PARP) in peripheral blood mononuclear cells secondary to treatment with ABT-888.

II. To determine the pharmacokinetics of ABT-888 in combination with oxaliplatin and capecitabine and the relation to treatment side effects.

OUTLINE: This is a dose-escalation study of veliparib.

Patients receive veliparib orally (PO) twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin intravenously (IV) over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood and urine sample collection at baseline and periodically during study for pharmacokinetic and poly (ADP-ribose) polymerase (PARP) inhibition studies.

After completion of study therapy, patients are followed up for 30 days.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • University of Wisconsin Hospital and Clinics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed solid tumors that fulfill ≥ 1 of the following criteria:

  • BRCA1/2 mutation and a BRCA-related malignancy

    • Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program
    • Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories
    • Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
    • Patients who refuse BRCA testing not allowed unless they have another acceptable histology
  • First- or second-line metastatic colorectal cancer
  • Any-line metastatic mucinous ovarian cancer
  • Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma)
• Patients with uncontrolled CNS metastasis are not eligible; patients with CNS metastases who have had them treated and are stable for > 3 months will be eligible; patients must be off steroid treatment prior to study enrollment

• Measurable disease

  • Patients with ovarian cancer who have a pre-treatment CA 125 level of at least twice the upper limit of normal allowed
• ECOG performance status (PS) 0-2 (Karnofsky 60-100%)
• Life expectancy > 3 months
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)
• Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
• Fertile patients must use adequate contraception (i.e., hormonal, barrier method of birth control, or abstinence)
• Not pregnant or nursing
• Negative pregnancy test
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study

• No uncontrolled intercurrent illness including, but not limited to, any of the following:

  • Ongoing or active infection
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • Psychiatric illness and/or social situations that would limit compliance with study requirements
• No history of positive serology for hepatitis A, B, or C, liver disease, or other forms of hepatitis or cirrhosis
• Patients who have active seizures or history of seizures are ineligible

• No condition that impairs the ability to swallow and retain veliparib capsules, including any of the following:

  • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
  • Prior surgical procedures affecting absorption
  • Active peptic ulcer disease
• No malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
• No peripheral neuropathy ≥ grade 2
• No prolonged QTC > 450 msec (male) or QTC > 470 (female)
• No concurrent combination antiretroviral therapy for HIV-positive patients

• Recovered from adverse events of prior therapy or prior surgical procedures

  • Patients with chronic grade 1 or 2 adverse events that are not expected to improve are allowed at investigator's discretion
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• At least 4 weeks since prior radiotherapy with no > 35% of marrow irradiation
• Prior fluoropyrimidine allowed
• Prior veliparib allowed provided it was part of a single- or limited-dosing study, such as a phase 0 study
• Prior capecitabine allowed provided patient tolerated 3500 mg/m² for 7 days out of 14 days
• No other prior investigational agents
• No prior oxaliplatin

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment (veliparib, capecitabine, oxaliplatin); Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Other: laboratory biomarker analysis; Correlative studies; Drug: oxaliplatin; Given IV; Other Names: 1-OHP; Dacotin; Dacplat; Eloxatin; L-OHP; Other: pharmacological study; Correlative studies; Other Names: pharmacological studies; Drug: capecitabine; Given PO; Other Names: Xeloda; CAPE; Ro 09-1978/000; Drug: veliparib; Given PO; Other Names: ABT-888

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum-tolerated (MTD) dose of veliparib in combination with oxaliplatin and capecitabine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	MTD defined as the dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT).	28 days
Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0		28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics of veliparib administered concomitantly with oxaliplatin and capecitabine	Graphical displays of individual, mean, and median plasma concentration over time will be presented at each ABT-888 dose level and overall in the entire group. Descriptive summaries for each pharmacokinetic endpoint will be presented by ABT-888 dose level.	At baseline, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours of days 1 and 7
Safety and tolerability as assessed by NCI CTCAE version 4.0	Reported in tabular format, both per dose level, as well as in the aggregate cohort.	Up to 30 days
Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)	Anti-tumor responses will be summarized using descriptive statistics and will be presented in tables. In addition, two-sided 90% confidence intervals for the proportions of subjects with a confirmed anti-tumor response will be obtained.	Up to 30 days

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: William Schelman, University of Wisconsin, Madison

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (Actual): October 1, 2013

Study Registration Dates

• First Submitted: November 2, 2010
• First Submitted That Met QC Criteria: November 2, 2010
• First Posted (Estimate): November 3, 2010

Study Record Updates

• Last Update Posted (Estimate): April 2, 2014
• Last Update Submitted That Met QC Criteria: April 1, 2014
• Last Verified: October 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Skin Diseases; Neoplasms by Histologic Type; Urogenital Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Genital Neoplasms, Female; Endocrine System Diseases; Disease Attributes; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Endocrine Gland Neoplasms; Breast Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Pancreatic Diseases; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms; Stomach Neoplasms; Neoplasms, Germ Cell and Embryonal; Breast Neoplasms; Recurrence; Adenocarcinoma; Ovarian Neoplasms; Rectal Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma; Colonic Neoplasms; Cystadenocarcinoma, Mucinous; Germinoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Poly(ADP-ribose) Polymerase Inhibitors; Capecitabine; Oxaliplatin; Veliparib
• Other Study ID Numbers: NCI-2011-02543 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); P30CA014520 (U.S. NIH Grant/Contract); U01CA062491 (U.S. NIH Grant/Contract); CDR0000687938; C010903 (Other Identifier: University of Wisconsin Hospital and Clinics); 8604 (CTEP)